* Neximmune Inc NEXI.OQ NEXI.O is expected to show no
change
in quarterly revenue when it reports results on May 10
(estimated).
*
* Refinitiv's mean analyst estimate for Neximmune Inc is
for a
loss of 46 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.
* Wall Street's median 12-month price target for Neximmune
Inc is
$3.5, above its last closing price of $0.34.
This summary was machine generated May 8 at 12:16 GMT. All
figures in US dollars unless otherwise stated